dianicline: an alpha4beta2 nicotinic receptor agonist; may be useful as an aid in quitting smoking; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10176764 |
| CHEMBL ID | 187927 |
| SCHEMBL ID | 2354672 |
| MeSH ID | M0546892 |
| Synonym |
|---|
| PDSP2_001278 |
| PDSP1_001294 |
| ssr-591813 |
| dianicline |
| ssr591813 |
| CHEMBL187927 , |
| (1r,10s)-9-oxa-4,13-diazatetracyclo[11.2.1.0^{1,10}.0^{3,8}]hexadeca-3,5,7-triene |
| bdbm50170601 |
| ssr 591813 |
| (5as,10ar)-6,7,9,10-tetrahydro-5ah,11h-8,10a-methanopyrido(2',3':5,6)pyrano(2,3-d)azepine |
| y0snm34c6o , |
| 5a,6,9,10-tetrahydro-7h,11h-8,10a-methanopyrido(2',3'-5,6)pyrano(2,3-d)azepine |
| 292634-27-6 |
| dianicline [inn] |
| ssr591813l |
| unii-y0snm34c6o |
| SCHEMBL2354672 |
| (5as,8s,10ar)-5a,6,9,10-tetrahydro-7h,11h-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine |
| DB12125 |
| Q5271647 |
| (1r,10s)-9-oxa-4,13-diazatetracyclo[11.2.1.01,10.03,8]hexadeca-3(8),4,6-triene |
| DTXSID30870314 |
| (1r,10s)-9-oxa-4,13-diazatetracyclo[11.2.1.0?,??.0?,?]hexadeca-3(8),4,6-triene |
| dianicline dihydrochloride |
| AKOS040741629 |
Dianicline is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dianicline is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine. " | ( Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Holme, I; Tonstad, S; Tønnesen, P, 2011) | 3.25 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Dianicline did not increase cigarette smoking abstinence rates beyond the initial phase of treatment. " | ( Dianicline, a novel α4β2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. Holme, I; Tonstad, S; Tønnesen, P, 2011) | 3.25 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neuronal acetylcholine receptor subunit beta-2 | Homo sapiens (human) | EC50 (µMol) | 100.0000 | 0.0000 | 1.5172 | 9.4000 | AID240102; AID240104 |
| Neuronal acetylcholine receptor subunit alpha-3 | Homo sapiens (human) | EC50 (µMol) | 100.0000 | 0.0070 | 2.2587 | 9.4000 | AID240102 |
| Neuronal acetylcholine receptor subunit alpha-4 | Homo sapiens (human) | EC50 (µMol) | 100.0000 | 0.0000 | 1.6186 | 9.4000 | AID240104 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID240102 | Effective concentration against Nicotinic acetylcholine receptor alpha3-beta2 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. |
| AID240104 | Effective concentration against Nicotinic acetylcholine receptor alpha4-beta2 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. |
| AID242877 | Maximal response against Nicotinic acetylcholine receptor alpha4-beta2 | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15 | Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (11.11%) | 5.53% |
| Reviews | 4 (44.44%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (44.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||